• Shingo Fujio, Tareq A Juratli, Kazunori Arita, Hirofumi Hirano, Yushi Nagano, Tomoko Takajo, Koji Yoshimoto, Ivanna V Bihun, Alexander B Kaplan, Naema Nayyar, Alexandria L Fink, Mia S Bertalan, Shilpa S Tummala, William T Curry, Pamela S Jones, Maria Martinez-Lage, Daniel P Cahill, Fred G Barker, and Priscilla K Brastianos.
• Divisions of Neuro-Oncology and Hematology/Oncology, Departments of Medicine and Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
• Neurosurgery. 2019 Aug 1; 85 (2): 204-210.

BackgroundPapillary craniopharyngiomas are characterized by BRAFV600E mutations. Targeted therapy can elicit a dramatic radiographic regression of these tumors. Therefore, prediction of BRAF mutation status before definitive surgery could enable neoadjuvant treatment strategies.ObjectiveTo establish preoperative prediction criteria to identify patients with a BRAF mutant craniopharyngioma.MethodsSixty-four patients with craniopharyngioma were included in this study. We determined BRAF mutation status by targeted sequencing. After scoring interobserver variability between presurgical clinical data and radiographic features, we established a diagnostic rule for BRAF mutation in our discovery cohort. We then validated the rule in an independent cohort.ResultsThe BRAFV600E mutation was detected in 12 of 42 patients in the discovery cohort. There were no patients under age 18 with BRAF mutation. Calcification was rare in tumors with BRAF mutation (P < .001), and 92% of them were supradiaphragmatic in location. Combining these 3 features-older than 18 years, absence of calcification, and supradiaphragmatic tumor location-we established a rule for predicting BRAF mutation. In cases where all 3 criteria were fulfilled, the sensitivity and specificity for the presence of BRAF mutation were 83% and 93%, respectively. In the validation cohort (n = 22), the sensitivity was 100% and specificity was 89%.ConclusionWe propose predictive criteria for a BRAF mutation in craniopharyngioma using preoperative clinical and radiographic data. This rule may be useful in identifying patients who could potentially benefit from neoadjuvant BRAFV600E-targeted systemic therapies.© Congress of Neurological Surgeons 2018.

26 keywords...

hide…